On November 3, 2026, JPMorgan Chase & Co. acquired 477,103 shares of SINOPHARM (01099) (H shares) by taking a security interest in shares via an off-exchange transaction at an average of HKD 16.6783 per share, involving about HKD 7.96 million, which was not matched on the SEHK open market (nature of consideration: cash).
Prior to the acquisition, JPMorgan Chase & Co.’s long position in SINOPHARM was 67.00 million shares, representing 4.99%; following the acquisition, the holding changed to 67.47 million shares, with the long position ratio rising to 5.02%.